Homologous and Heterologous Skin Transplantation in Patients With Lymphomatous Disease

Abstract
Forty-three patients with lymphomatous disease received homologous skin transplants. In 19, survival of the graft was prolonged. Nine patients who had received human skin grafts also received pigskin transplants. In 2, survival was prolonged. There was no consistent correlation between ability to accept or reject homografts and type of therapy administered, the titer of isohemagglutinins, response to typhoid-paratyphoid vaccination, skin testing with tuberculin, mumps, and Candida albicans antigens or properdin titers. Graft survival was not prolonged in the 4 patients with hypogammaglobulinemia. There were patients with chronic lymphatic leukemia, Hodgkin's disease, lymphosarcoma, reticulum-cell sarcoma, and multiple myeloma in both the typical-rejection and prolonged-survival groups. Two patients with chronic myelogenous leukemia and 1 with acute leukemia had typical homograft rejections.